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Abstract
Recently, nonalcoholic steatohepatitis (NASH) has been 
considered to be another cause of liver cirrhosis and 
hepatocellular carcinoma (HCC). The natural history and 
prognosis of NASH are controversial. Accordingly, we as-
sessed the clinicopathological features of NASH-associ-
ated HCC in our experience and reviewed the literature 
of NASH-associated HCC. We experienced 11 patients 
with NASH-associated HCC (6 male, 5 female; mean 
age 73.8 ± 4.9 years) who received curative treat-
ments. Most (91%) patients had been diagnosed with 
obesity, diabetes, hypertension, or dyslipidemia. Seven 
patients (64%) also had a non-cirrhotic liver. The recur-
rence-free survival rates at 1, 3 and 5 years were 72%, 
60%, and 60%. We also summarized and reviewed 94 
cases of NASH-associated HCC which were reported in 
the literature (64 male; mean age 66 years). The ma-
jority of patients (68%) were obese, 66% of patients 
had diabetes, and 24% had dyslipidemia. Furthermore, 
26% of the HCCs arose from the non-cirrhotic liver. In 
conclusion, patients with non-cirrhotic NASH may be 
a high-risk group for HCC, and regular surveillance for 
HCC is necessary in non-cirrhotic NASH patients as well 
as cirrhotic patients. 
© 2010 Baishideng. All rights reserved.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is a common malig-
nancy in Asia and South Africa. HCC usually develops in 
patients with hepatitis B, hepatitis C, and alcoholic liver 
disease. Recently, nonalcoholic steatohepatitis (NASH) 
has been considered to be another cause of  liver cir-
rhosis and HCC. Powell et al[1] reported the first case of  
NASH-associated HCC. Since then, several case series 
of  NASH-associated HCC have been reported[2-4].
The prevalence of  nonalcoholic fatty liver disease 
(NAFLD) is 10%-30% in adults[5] and its prevalence is in-
creasing in Japan as well as Western countries because of  
the epidemic rise in obesity and diabetes mellitus (DM). 
NASH is part of  the spectrum of  NAFLD, and 20% of  
NASH cases are thought to slowly progress to cirrhosis[6]. 
According to a previous study[7], NASH can progress 
to cirrhosis and result in complications including HCC. 
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Almost all patients with cryptogenic cirrhosis (CC) had 
clinical features consistent with NASH, but a diagnosis of  
NASH could not be confirmed by histology (likely “burnt 
out NASH”)[8]. The natural history and prognosis of  
NASH is controversial, because there are few reports on 
prospective cohort studies of  NASH[9,10]. Accordingly, it is 
necessary to clarify an etiology and a prognosis of  NASH-
associated HCC. Thus, we retrospectively assessed the 
clinicopathological features of  NASH-associated HCC 
in our experience and reviewed the literature on NASH-
associated HCC. 
NASH-ASSOCIATED HCC IN OUR 
EXPERIENCE
We reviewed 797 consecutive patients treated for pri-
mary HCC at National Hospital Organization Iwakuni 
Clinical Center from January 1996 and September 2008. 
Of  these, 445 with HCC initially underwent curative 
treatment. Curative treatment was defined as complete 
tumor eradication, with no residual tumor visible by 
computed tomography (CT), or resection of  all evident 
tumor tissue, and no tumors detected in the remnant liv-
er on CT scan performed 3 to 4 wk after curative treat-
ment. Curative treatment included surgery, percutaneous 
radiofrequency ablation (RFA), microwave coagulation 
therapy (MCT), and percutaneous ethanol injection (PEI). 
Within this group, 11 patients were considered to have 
NASH based on the histology of  the non-cancerous 
parts of  the surgical specimens or biopsy specimens. 
NASH was diagnosed using the following criteria[3]: 
(1) histological features of  steatohepatitis; (2) intake of  
less than 20 g ethanol per day; (3) absence of  other liver 
diseases such as autoimmune hepatitis, drug-induced liver 
disease, primary biliary cirrhosis, primary sclerosing chol-
angitis, and metabolic liver disease such as Wilson’s disease 
and hemochromatosis; and (4) negative for hepatitis B 
surface antigen and antibody to hepatitis C virus (HCV) 
and/or negative for HCV RNA on polymerase chain re-
action analysis. 
The body mass index (BMI) was calculated as body 
weight in kilograms divided by the square of  the height 
in meters (kg/m2). The definition of  DM was fasting 
plasma glucose level ≥ 126 mg/dL on at least two oc-
casions, plasma glucose level of  ≥ 200 mg/dL at 2 h in 
a 75 g oral glucose tolerance test, or the need for insulin 
or an oral antihyperglycemic drug to control glucose 
levels. The oral glucose tolerance test was undertaken by 
patients who had no medical history of  DM.
Dyslipidemia was defined as blood total cholesterol 
concentration > 220 mg/dL or triglyceride > 150 mg/dL 
or a history of  taking oral drugs for dyslipidemia. 
The histological status of  underlying liver disease was 
based upon microscopic examination of  the non-cancer-
ous part of  the surgical specimen or biopsy specimen with 
hematoxylin-eosin and Azan staining. All liver tissue speci-
mens were evaluated by two senior pathologists who were 
unaware of  the laboratory data and the clinical course. 
Steatohepatitis was pathologically graded on quantified 
steatosis, ballooning degeneration, and lobular inflamma-
tion to produce an NAFLD activity score (NAS)[11]. When 
this score is ≥ 5 it is diagnostic for NASH. The extent of  
fibrosis, established by Desmet et al[12], is as follows: F0 (no 
fibrosis), F1 (mild fibrosis), F2 (moderate fibrosis), and F3 
(severe fibrosis) were all categorized non-cirrhosis. F4 was 
categorized as cirrhosis. 
A summary of  our 11 cases with NASH-associated 
HCC is shown in Table 1. The mean age of  patients with 
HCC was 73.8 ± 4.9 years. Of  the 11 patients, 6 patients 
(55%) were male, and 5 (45%) were female. The mean 
BMI was 24.8 kg/m2. Six patients (55%) were obese (BMI 
≥ 25 kg/m2), 6 (55%) had DM, 3 (27%) had dyslipid-
emia, and 6 (55%) had hypertension. Ten patients (91%) 
had obesity or at least 1 comorbid illness. The prevalence 
of  positivity of  HBV core (HBc) antibodies in our cases 
was 27% (3 of  11 patients). Ten patients (91%) had 
Child-Pugh classification A and 1 (9%) was Child-Pugh 
classification B, and all patients received curative treat-
ments as outlined below. Seven patients (64%) received 
surgery, 3 patients (27%) received RFA, and 1 patient (9%) 
received MCT. Four patients (36%) had concomitant liver 
cirrhosis (F4), and 7 patients (64%) had a non-cirrhotic 
liver (F1-3). Concerning the characteristics of  HCC, 8 
patients (73%) had a single nodule, 3 patients (27%) had 
multinodular lesions, and the mean size of  the largest le-
sion was 3.3 ± 1.3 cm (range 1.7-5.0 cm). 
Patients were followed for 41.3 ± 40.0 mo (range, 
9.4-151.7 mo), and no patients dropped out. Local tumor 
progression was not found. The recurrence-free survival 
rates at 1, 3, and 5 years calculated by Kaplan-Meier meth-
od were 72%, 60%, and 60% (Figure 1). All of  tumor 
recurrences were observed within the first 2 years, and no 
recurrence was observed after 2 years. During the follow-
up, 3 patients (27%) died as a result of  HCC (2 patients) 
and hepatic failure (1 patient).
EPIDEMIOLOGIC TRENDS OF NASH AND 
NASH-ASSOCIATED HCC
HCC is the third leading cause of  cancer death in world-
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Figure 1  Recurrence-free survival rates in nonalcoholic steatohepatitis 
(NASH)-associated hepatocellular carcinoma (HCC). 
wide; there are an estimated 500 000 to 1 million new 
cases each year resulting in 600 000 deaths annually[13]. 
The major causes of  cirrhosis seen in HCC are viral 
(hepatitis B, hepatitis C), and alcohol. HCV infection 
is the most prevalent risk factor for HCC in Japan and 
United States. In United States, the most leading etiology 
underlying liver disease among the patients with HCC 
was HCV (51%), and the second most common etiology 
was CC (29%)[14].
In the majority of  CC cases it is thought to be end-
stage NASH because some clinical features such as obesity 
and diabetes in CC patients are linked to NASH. Howev-
er, histology often is no longer informative when cirrhosis 
is already established[15] because it has been theorized that 
CC often represents “burned out” NASH. Marrero et al[16] 
studied the etiology of  liver disease in 150 patients with 
HCC wherein NAFLD-related CC accounted for at least 
13% of  the cases. 
CLINICOPATHOLOGICAL FEATURES 
Articles were searched in Medline and Pubmed. The 
search terms used were NASH, nonalcoholic steato-
hepatitis, fatty liver, HCC, hepatocellular carcinoma, 
hepatoma, and liver neoplasms. We summarized and re-
viewed several studies and numerous case reports which 
explored NASH-associated HCC[1-4,17-31]. At least 94 cases 
of  NASH-associated HCC were reported (Table 2). Sixty-
four patients were male (64%), and the age at diagnosis 
ranged from 35 to 89 years (mean, 66 years). The majority 
of  patients (68%) were obese, 66% of  patients had DM, 
and 24% had dyslipidemia. Concerning tumor character-
istics, 69% of  HCCs were multinodular, maximum tumor 
size ranged from 1.4-13 cm (mean, 3.5 cm). Furthermore, 
26% of  cases arose from a non-cirrhotic liver. In a case-
controlled study of  34 Japanese NASH-associated HCC 
patients, those patients were predominantly male, had a 
median age of  70 years and 88% had advanced fibrosis. 
Older age, low level of  AST, low grade of  activity, and ad-
vanced fibrosis were independent predictors of  develop-
ing HCC in NASH[3]. 
NATURAL HISTORY AND PROGNOSTIC 
FACTORS 
The natural history and prognosis of  NASH is contro-
versial because there are few reports on prospective co-
hort studies of  NASH[3,9,10].
Yatsuji et al[10] reported that the 5-year HCC rate was 
11.3% for NASH-cirrhosis and 30.5% for HCV-cirrho-
sis in Japanese patients. On the other hand, Hui et al[9] 
reported that HCC occurred in 8 (17%) of  46 patients 
with HCV-cirrhosis compared with none of  23 patients 
with NASH-cirrhosis after 5 years follow-up in Australia. 
A prospective cohort study of  NASH patients in 
Japan[3] showed that the 5-year cumulative incidence of  
HCC was 7.6%, and the 5-year survival rate was 82.8%. 
Concerning outcome, 26 of  137 NASH patients died, 
with death caused by liver failure in 7 patients, HCC in 
12 patients and other causes in 7 patients. Liver-related 
deaths thus accounted for 19 (73%) deaths.
Malik et al[4] reported that the survival rate after liver 
transplantation for HCC complicated NASH-cirrhosis 
was 88% at a mean follow-up of  2.5 years. There was no 
difference in 5-year survival between patients transplanted 
for NASH-cirrhosis with and without HCC, and no differ-
ence in 5-year survival after liver transplantation between 
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Table 1  Characteristics of 11 NASH patients with HCC undergoing curative treatment
Case 1 2 3 4 5 6 7 8 9 10 11
Sex (M/F) M F F M M M F F F F M
Age (yr) 73 73 83 75 67 68 77 79 73 76 68
BMI    25.0    23.6    21.0    22.3   25.3    24.2    28.1    25.3    23.4    28.8    26.2
Diabetes mellitus (yes/no) No Yes Yes Yes No Yes Yes No No No Yes
Dyslipidemia (yes/no) No Yes No Yes No No No No No No Yes
Hypertension (yes/no) No Yes No Yes Yes No Yes Yes No No Yes
Total bilirubin (mg/dL)      1.6      0.6      0.6     0.7     1.4     0.8      0.8      1.2      0.6      1.3      0.9
Albumin (g/dL)      3.9      4.4      3.2      3.8     4.4     4.3      3.5      4.1      4.4      3.8      4.9
ALT (IU/L) 73 41 22 24 73 18 19 29 41 40 57
γGTP (IU/L)      110 45 36 22 57 33 26      111      124 41      177
Prothrombin time (%)    78.1    95.8    96.3  106.6   90.9 113.4    75.4    77.2    94.0    68.4    86.0
Platelets (× 104/μL)    10.1    15.0    15.1   27.8   14.3   27.2      9.3   13.9    13.0      5.5    13.4
Child-Pugh classification (A/B) A A A A A A B A A A A
AFP (ng/mL)     8.7      4.6    40.6 9181.6     1.7      1.8 1957.0      7.9    13.0      8.8    16.2
DCP (mAU/mL) 31 10    2066    1765 64 10      718 19      571      106    2930
Anti-HBc (+/-) + - - - - + - - - + -
Treatment (RFA/MCT/Ope) RFA RFA Ope Ope Ope Ope Ope Ope RFA MCT Ope
No. of nodules (1/2/3)   3   1   1   1  1   1   1   1   3   2   1
Size of largest tumor (cm)      1.8      1.7      5.0     5.0     3.6     4.5      3.2      2.0      2.5      3.0      4.4
Stage of fibrosis (F1/F2/F3/F4) F4 F1 F4 F1 F1 F1 F4 F4 F1 F3 F1
NASH: Nonalcoholic steatohepatitis; HCC: Hepatocellular carcinoma; M: Male; F: Female; BMI: Body mass index; ALT: Alanine aminotransferase; γGTP: 
γ-glutamyltransferase; AFP: a-fetoprotein; DCP: Des-γ-carboxy prothrombin; Anti-HBc: HBc antibody; RFA: Radio-frequency ablation; MCT: Microwave 
coagulation therapy; Ope: Operation.
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HCC patients with NASH-cirrhosis and with non-NASH-
cirrhosis (HCV, HBV, alcoholic, CC, and otherwise). They 
concluded that patients with NASH and HCC have a 
good outcome after liver transplantation.
Giannini et al[32] reported that patients with CC had a 
significantly greater prevalence of  advanced HCC stage, 
lower amenability to any treatment, and shorter survival 
times compared with HCV patients, because HCC in CC 
patients is often diagnosed at an advanced stage owing 
to lack of  surveillance.
MECHANISMS OF NASH-INDUCED 
HEPATOCARCINOGENESIS
Although the mechanism of  carcinogenesis in patients 
with NASH remains uncertain, insulin resistance and 
oxidative stress may be involved in carcinogenesis of  
NASH.
NASH is characterized by insulin resistance with 
hyperinsulinaemia, and the resistance is thought to be in-
volved in hepatocarcinogenesis. Insulin-like growth fac-
tor 1 (IGF-1)[33] significantly activated mitogen-activated 
protein kinase (MAPK), and increased overexpression 
of  the c-fos and c-jun proto-oncogenes in cultured hep-
atoma cells[34].
Adiponectin and leptin are associated with insulin re-
sistance. Severe liver steatosis and fibrosis were observed 
in adiponectin knockout (KO) mice as compared with 
wild type (WT) mice[35]. Furthermore, liver adenoma and 
hyperplastic nodules developed in an adiponectin KO 
mouse, whereas no tumor was detected in WT mice. 
In animal models, leptin-mediated neovascularization, 
which coordinated with VEGF, produced liver fibrosis 
and hepatocarcinogenesis in NASH[36].
NASH-associated insulin resistance causes inhibi-
tion of  hepatic mitochondrial fatty acid oxidation and 
increased intracellular fatty acids may lead to oxidative 
DNA damage by stimulating microsomal peroxidases[37].
Oxidative stress may also promote carcinogenesis. 
Trans-4-hydroxy-2-nonenal, a major electrophilic by-
product of  lipid peroxidation caused by oxidative stress 
may be an important etiological agent for HCC via muta-
tion at codon 249 of  the p53 gene[38]. 
Reactive oxygen species (ROS) can activate fibrosis[39]. 
Furthermore, the major products of  lipid peroxidation, 
malondialdehyde, stimulates DNA mutations[40]. There-
fore, inflammation is a risk factor for various carcino-
mas[41]. Oxidative stress has inactivated the expression of  
Nrf1 gene that regulates gene transcription encoding enzy-
matic antioxidants. Recently, in an animal model, oxidative 
stress inactivation of  the Nrf1 gene in the liver has been 
reported to spontaneously produce HCC when oxidative 
injury was present before tumor formation[42].
Ishii et al[43] reported that in animal models, eicosa-
pentaenoic acid (EPA) ameliorated steatohepatitis with 
decreasing serum ROS, which consequently inhibited 
development of  HCC. Medical treatment with EPA may 
minimize the risk of  HCC development in patients with 
NASH.
CONCLUSION
Most (91%) patients with NASH-associated HCC in our 
experience had been diagnosed with obesity, diabetes, 
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Table 2  Clinical features of cases with NASH-associated HCC in previous reports
Author No. of 
cases
Age
(yr)
Sex Underlying disease Liver histology No. of nodules Tumor 
size (cm)
Treatment
Powell et al[1] 1 57 F DM LC Mul NR Ope
Zen et al[17] 1 72 F DM LC Mul 1.4 NR
Orikasa et al[18] 1 67 F DM LC Sol 2.6 NR
Cotrim et al[19] 1 66 M OB, DM LC Sol 3.0 PEI
Bencheqroun et al[20] 1 68 M OB Non-LC NR NR NR
Mori et al[21] 1 76 M OB, DM LC Sol 1.9 RFA
Bullock et al[22] 2 64, 74 M (2) OB (2), DM (2) Non-LC (2) Sol (2) NR Ope (2)
Cuadrado et al[23] 2 69, 74 M (2) OB (2), DM (2) LC, Non-LC Sol (2) NR RFA (2)
Sato et al[24] 1 64 M OB, DL Non-LC Sol     13.0 None
Ichikawa et al[25] 2 60, 66 M, F OB (1), DL (1) Non-LC (2) Sol (2) 1.5, 2.5 Ope (2)
Ikeda et al[26] 1 69 M OB, DM LC Sol 4.5 Ope
Tsutsumi et al[27] 2 46, 68 M, F NR LC (2) Sol (2) NR NR
Hashizume et al[2] 9 45-82 M (5), F (4) OB (5), DM (7), DL (8) LC (6), Non-LC (3) Sol (8), Mul (1) 1.5-7.0 Ope (6), RFA (2), 
TAE (1)
Hai et al[28] 2 65, 72 M (2) OB (2), DM (2) LC, Non-LC Sol (2) 4.0, 6.0 Ope (2)
Maeda et al[29] 3 52-68 M (2), F (1) NR LC (3) Sol (3) 1.3-5.0 Ope (3)
Kawada et al[30] 6 59-81 M (3), F (3) OB (2), DM (3), DL (1) Non-LC (6) Sol (6) 1.3-5.8 Ope (6)
Hashimoto et al[3] 34 54-89 M (21), F (13) OB (62%), DM (74%), DL (29%) F1-2 (22%), F3-4 (88%) Sol (24), Mul (10) NR NR
Malik et al[4] 17 47-72 M (12), F (5) OB (17), DM (12) LC (17) Sol (8), Mul (9) 1.1-8.0 LT (17)
Chagas et al[31] 7 35-77 M (4), F (3) OB (7), DM (3), DL (2) LC (6), Non-LC (1) Sol (4), Mul (3) 2.8-5.2 Ope (2), PEI (1), 
TAE (3), LT (1)
HCC: Hepatocellular carcinoma; DM: Diabetes mellitus; OB: Obesity; DL: Dyslipidemia; LC: Liver cirrhosis; Mul: Multiple; Sol: Solitary; Ope: Surgical 
operation; PEI: Percutaneous ethanol injection; RFA: Radiofrequency ablation; TAE: Transarterial embolization; LT: Liver transplantation; NR: Not 
reported.
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hypertension, or dyslipidemia. CC patients had these co-
morbid illnesses, and CC had clinical features consistent 
with NASH. 
Occult HBV infection might be a possible etiologic 
agent of  HCC, and the prevalence of  past/occult HBV 
infection via positivity of  HBc antibody in our cases was 
27%. Negativity of  HBc antibody is not necessarily a 
required item of  diagnosis for NASH, and liver speci-
mens of  these HBc antibody positive patients had no 
histological features of  chronic hepatitis B.
Although almost NASH-associated HCC was ac-
companied by liver cirrhosis according to previous re-
ports[1,17-19], the majority of  our case series were accompa-
nied by non-cirrhotic liver. 
Furthermore, recent case reports[2,30] about HCC aris-
ing from non-cirrhotic NASH have been accumulating. 
One possible explanation for this difference between 
our cases and other previous reports is that almost all 
patients with CC had clinical features consistent with 
NASH, but a diagnosis of  NASH could not be con-
firmed by histology (likely “burnt out NASH”).
All cases of  tumor recurrence in our series were 
observed within the first 2 years, no recurrence was ob-
served after 2 years. These recurrence patterns of  HCC 
suggested that the recurrence of  HCC might be based on 
intrahepatic metastasis rather than multicentric carcino-
genesis. NASH-associated HCC patients with non-cura-
tive treatments were not observed in our cases, because 
these patients did not receive liver biopsy or surgery. The 
existence of  selection bias is unavoidable.
In conclusion, patients with non-cirrhotic NASH 
may be a high-risk group for HCC, and regular surveil-
lance for HCC is necessary for non-cirrhotic NASH pa-
tients as well as cirrhotic patients. 
REFERENCES
1 Powell EE, Cooksley WG, Hanson R, Searle J, Halliday 
JW, Powell LW. The natural history of nonalcoholic 
steatohepatitis: a follow-up study of forty-two patients for 
up to 21 years. Hepatology 1990; 11: 74-80
2 Hashizume H, Sato K, Takagi H, Hirokawa T, Kojima A, 
Sohara N, Kakizaki S, Mochida Y, Shimura T, Sunose Y, 
Ohwada S, Mori M. Primary liver cancers with nonalcoholic 
steatohepatitis. Eur J Gastroenterol Hepatol 2007; 19: 827-834
3 Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N, Toku-
shige K, Shiratori K. Hepatocellular carcinoma in patients 
with nonalcoholic steatohepatitis. J Gastroenterol 2009; 44 
Suppl 19: 89-95
4 Malik SM, Gupte PA, de Vera ME, Ahmad J. Liver trans-
plantation in patients with nonalcoholic steatohepatitis-
related hepatocellular carcinoma. Clin Gastroenterol Hepatol 
2009; 7: 800-806
5 Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki 
S. Increase in the prevalence of fatty liver in Japan over the 
past 12 years: analysis of clinical background. J Gastroenterol 
2003; 38: 954-961
6 Harrison SA, Torgerson S, Hayashi PH. The natural history 
of nonalcoholic fatty liver disease: a clinical histopathological 
study. Am J Gastroenterol 2003; 98: 2042-2047
7 Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, 
Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, 
Rizzetto M. Expanding the natural history of nonalcoholic 
steatohepatitis: from cryptogenic cirrhosis to hepatocellular 
carcinoma. Gastroenterology 2002; 123: 134-140
8 Yoshioka Y, Hashimoto E, Yatsuji S, Kaneda H, Taniai M, 
Tokushige K, Shiratori K. Nonalcoholic steatohepatitis: 
cirrhosis, hepatocellular carcinoma, and burnt-out NASH. J 
Gastroenterol 2004; 39: 1215-1218
9 Hui JM, Kench JG, Chitturi S, Sud A, Farrell GC, Byth K, 
Hall P, Khan M, George J. Long-term outcomes of cirrhosis 
in nonalcoholic steatohepatitis compared with hepatitis C. 
Hepatology 2003; 38: 420-427
10 Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, 
Shiratori K. Clinical features and outcomes of cirrhosis due to 
non-alcoholic steatohepatitis compared with cirrhosis caused 
by chronic hepatitis C. J Gastroenterol Hepatol 2009; 24: 248-254
11 Nonalcoholic steatohepatitis clinical research network. Hepa­
tology 2003; 37: 244
12 Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. 
Classification of chronic hepatitis: diagnosis, grading and 
staging. Hepatology 1994; 19: 1513-1520
13 Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-
Robinson SD. Hepatocellular carcinoma: epidemiology, 
risk factors and pathogenesis. World J Gastroenterol 2008; 14: 
4300-4308
14 Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick 
DM, Lok AS. NAFLD may be a common underlying liver 
disease in patients with hepatocellular carcinoma in the 
United States. Hepatology 2002; 36: 1349-1354
15 Ayata G, Gordon FD, Lewis WD, Pomfret E, Pomposelli 
JJ, Jenkins RL, Khettry U. Cryptogenic cirrhosis: clinico-
pathologic findings at and after liver transplantation. Hum 
Pathol 2002; 33: 1098-1104
16 Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick 
DM, Lok AS. NAFLD may be a common underlying liver 
disease in patients with hepatocellular carcinoma in the 
United States. Hepatology 2002; 36: 1349-1354
17 Zen Y, Katayanagi K, Tsuneyama K, Harada K, Araki I, 
Nakanuma Y. Hepatocellular carcinoma arising in non-
alcoholic steatohepatitis. Pathol Int 2001; 51: 127-131
18 Orikasa H, Ohyama R, Tsuka N, Eyden BP, Yamazaki K. 
Lipid-rich clear-cell hepatocellular carcinoma arising in non-
alcoholic steatohepatitis in a patient with diabetes mellitus. 
J Submicrosc Cytol Pathol 2001; 33: 195-200
19 Cotrim HP, Paraná R, Braga E, Lyra L. Nonalcoholic 
steatohepatitis and hepatocellular carcinoma: natural history? 
Am J Gastroenterol 2000; 95: 3018-3019
20 Bencheqroun R , Duvoux C, Luciani A, Zafrani ES, 
Dhumeaux D. [Hepatocellular carcinoma without cirrhosis 
in a patient with nonalcoholic steatohepatitis] Gastroenterol 
Clin Biol 2004; 28: 497-499
21 Mori S, Yamasaki T, Sakaida I, Takami T, Sakaguchi E, 
Kimura T, Kurokawa F, Maeyama S, Okita K. Hepatocellular 
carcinoma with nonalcoholic steatohepatitis. J Gastroenterol 
2004; 39: 391-396
22 Bullock RE, Zaitoun AM, Aithal GP, Ryder SD, Beckingham 
IJ, Lobo DN. Association of non-alcoholic steatohepatitis 
without significant fibrosis with hepatocellular carcinoma. J 
Hepatol 2004; 41: 685-686
23 Cuadrado A, Orive A, García-Suárez C, Domínguez A, 
Fernández-Escalante JC, Crespo J, Pons-Romero F. Non-
alcoholic steatohepatitis (NASH) and hepatocellular carcino-
ma. Obes Surg 2005; 15: 442-446
24 Sato K, Ueda Y, Ueno K, Okamoto K, Iizuka H, Katsuda S. 
Hepatocellular carcinoma and nonalcoholic steatohepatitis 
developing during long-term administration of valproic 
acid. Virchows Arch 2005; 447: 996-999
25 Ichikawa T, Yanagi K, Motoyoshi Y, Hamasaki K, Nakao 
K, Toriyama K, Eguchi K. Two cases of non-alcoholic steato-
hepatitis with development of hepatocellular carcinoma 
without cirrhosis. J Gastroenterol Hepatol 2006; 21: 1865-1866
26 Ikeda H, Suzuki M, Takahashi H, Kobayashi M, Okuse 
1440 March 28, 2010|Volume 16|Issue 12|WJG|www.wjgnet.com
Takuma Y et al . NASH-associated HCC
N, Moriya H, Koike J, Maeyama S, Yotsuyanagi H, Itoh F. 
Hepatocellular carcinoma with silent and cirrhotic non-
alcoholic steatohepatitis, accompanying ectopic liver tissue 
attached to gallbladder. Pathol Int 2006; 56: 40-45
27 Tsutsumi K, Nakayama H, Sakai Y, Kojima Y, Dairaku N, 
Ojima T, Kusano M, Ikeya S, Sugai Y, Hiwatashi N. [Two 
cases of patients with hepatocellular carcinoma (HCC) that 
developed in cryptogenic cirrhosis suggestive of nonalcoholic 
steatohepatitis (NASH) as background liver disease after 
clinical courses of 26 years] Nippon Shokakibyo Gakkai Zasshi 
2007; 104: 690-697
28 Hai S, Kubo S, Shuto T, Tanaka H, Takemura S, Yamamoto 
T, Kanazawa A, Ogawa M, Hirohashi K, Wakasa K. Hepato-
cellular carcinoma arising from nonalcoholic steatohepatitis: 
report of two cases. Surg Today 2006; 36: 390-394
29 Maeda T, Hashimoto K, Kihara Y, Ikegami T, Ishida T, 
Aimitsu S, Fujiwara M. Surgically resected hepatocellular 
carcinomas in patients with non-alcoholic steatohepatitis. 
Hepatogastroenterology 2008; 55: 1404-1406
30 Kawada N, Imanaka K, Kawaguchi T, Tamai C, Ishihara R, 
Matsunaga T, Gotoh K, Yamada T, Tomita Y. Hepatocellular 
carcinoma arising from non-cirrhotic nonalcoholic 
steatohepatitis. J Gastroenterol 2009; 44: 1190-1194
31 Chagas AL, Kikuchi LO, Oliveira CP, Vezozzo DC, Mello 
ES, Oliveira AC, Cella LC, Herman P, Bachella T, Caldwell 
SH, Alves VA, Carrilho FJ. Does hepatocellular carcinoma 
in non-alcoholic steatohepatitis exist in cirrhotic and non-
cirrhotic patients? Braz J Med Biol Res 2009; 42: 958-962
32 Giannini EG, Marabotto E, Savarino V, Trevisani F, di Nolfo 
MA, Del Poggio P, Benvegnù L, Farinati F, Zoli M, Borzio 
F, Caturelli E, Chiaramonte M. Hepatocellular carcinoma in 
patients with cryptogenic cirrhosis. Clin Gastroenterol Hepatol 
2009; 7: 580-585
33 Buzzelli G, Dattolo P, Pinzani M, Brocchi A, Romano S, 
Gentilini P. Circulating growth hormone and insulin-like 
growth factor-I in nonalcoholic liver cirrhosis with or without 
superimposed hepatocarcinoma: evidence of an altered 
circadian rhythm. Am J Gastroenterol 1993; 88: 1744-1748
34 Price JA, Kovach SJ, Johnson T, Koniaris LG, Cahill PA, 
Sitzmann JV, McKillop IH. Insulin-like growth factor I is a 
comitogen for hepatocyte growth factor in a rat model of 
hepatocellular carcinoma. Hepatology 2002; 36: 1089-1097
35 Asano T, Watanabe K, Kubota N, Gunji T, Omata M, 
Kadowaki T, Ohnishi S. Adiponectin knockout mice on 
high fat diet develop fibrosing steatohepatitis. J Gastroenterol 
Hepatol 2009; 24: 1669-1676
36 Kitade M, Yoshiji H, Kojima H, Ikenaka Y, Noguchi R, 
Kaji K, Yoshii J, Yanase K, Namisaki T, Asada K, Yamazaki 
M, Tsujimoto T, Akahane T, Uemura M, Fukui H. Leptin-
mediated neovascularization is a prerequisite for progression 
of nonalcoholic steatohepatitis in rats. Hepatology 2006; 44: 
983-991
37 Yang S, Zhu H, Li Y, Lin H, Gabrielson K, Trush MA, Diehl 
AM. Mitochondrial adaptations to obesity-related oxidant 
stress. Arch Biochem Biophys 2000; 378: 259-268
38 Hu W, Feng Z, Eveleigh J, Iyer G, Pan J, Amin S, Chung FL, 
Tang MS. The major lipid peroxidation product, trans-4-
hydroxy-2-nonenal, preferentially forms DNA adducts at 
codon 249 of human p53 gene, a unique mutational hotspot in 
hepatocellular carcinoma. Carcinogenesis 2002; 23: 1781-1789
39 Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 
2002; 346: 1221-1231
40 Marnett LJ. Oxyradicals and DNA damage. Carcinogenesis 
2000; 21: 361-370
41 Coussens LM, Werb Z. Inflammation and cancer. Nature 
2002; 420: 860-867
42 Xu Z, Chen L, Leung L, Yen TS, Lee C, Chan JY. Liver-
specific inactivation of the Nrf1 gene in adult mouse leads 
to nonalcoholic steatohepatitis and hepatic neoplasia. Proc 
Natl Acad Sci USA 2005; 102: 4120-4125
43 Ishii H, Horie Y, Ohshima S, Anezaki Y, Kinoshita N, 
Dohmen T, Kataoka E, Sato W, Goto T, Sasaki J, Sasaki T, 
Watanabe S, Suzuki A, Ohnishi H. Eicosapentaenoic acid 
ameliorates steatohepatitis and hepatocellular carcinoma in 
hepatocyte-specific Pten-deficient mice. J Hepatol 2009; 50: 
562-571
S- Editor  Wang YR    L- Editor  O’Neill M    E- Editor  Ma WH
1441 March 28, 2010|Volume 16|Issue 12|WJG|www.wjgnet.com
Takuma Y et al . NASH-associated HCC
